Log in
Donate

Clinical Trial: ECOG-ACRIN EA1181

ECOG-ACRIN EA1181

Status: Closed

NCT#04266249

(CompassHER2-pCR): Preoperative THP and Postoperative HP in Patients Who Achieve a Pathologic Complete Response Part 1 Component of: The CompassHER2 Trials (COMprehensive Use of Pathologic Response ASSessment to Optimize Therapy in HER2-Positive Breast Cancer)

EA1181 is closed to accrual, effective October 19, 2023.

EA1181 ER-Negative Cohort is closed to accrual, effective May 25, 2023.

EA1181 HER2+/ER+ Subset with tumor size 2.1-3.0 cm and node negative is closed to accrual, effective July 27, 2022.

View All Clinical Trials
The Montana Cancer Consortium (MCC) is an independent nonprofit organization whose mission is to bring state-of-the-art cancer care to Montana, Idaho and Wyoming through National Cancer Institute (NCI) sponsored clinical research.

Navigation

About Us

Contact Us

Copyright © Montana Cancer Consortium | All rights reserved